Clinical Trial Update: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients [Phase 3]

View source ↗

Summary

Phase 3 trial of valganciclovir (Valcyte) for prevention of cytomegalovirus disease in kidney transplant recipients completed; results were posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• Valcyte (valganciclovir)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Cytomegalovirus Infections | Phase 3 | Status: COMPLETED | Results posted: 2010-07-05